Print Page    Close Window

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)


0.00 (0.00%)

Market Cap$200,552,851

07/24/17  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $18.92 with a 52 week high of $19.00 and a 52 week low of $7.25.

Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients


Read More

Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference


Read More

Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch


Read More

There are currently no events scheduled.